Long-term Study of KAD-1229 in Type 2 Diabetes Patients
Primary Purpose
Type 2 Diabetes
Status
Completed
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
KAD-1229
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring Type 2 diabetes, HbA1c, Long-term study
Eligibility Criteria
Inclusion Criteria:
- Type 2 diabetes patients who show inadequate glycemic control with diet, and biguanide or DPP-4 inhibitor monotherapy
- Age in the 20 years or over inclusive
- HbA1c in the range of ≥ 6.5 to < 9%
Exclusion Criteria:
- Type 1 diabetes mellitus
- Patients with serious diabetic complications and other serious complications
Sites / Locations
- Japan
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
KAD-1229
Arm Description
Outcomes
Primary Outcome Measures
Incidences of Adverse Events
Secondary Outcome Measures
Change From Baseline in HbA1c at 52 Weeks
Full Information
NCT ID
NCT01333592
First Posted
April 6, 2011
Last Updated
November 27, 2014
Sponsor
Kissei Pharmaceutical Co., Ltd.
1. Study Identification
Unique Protocol Identification Number
NCT01333592
Brief Title
Long-term Study of KAD-1229 in Type 2 Diabetes Patients
Official Title
A Multicenter, Open Label, Long-term Study of KAD-1229 in Type 2 Diabetes Patients Who Show Inadequate Glycemic Control With Diet, and Biguanide or DPP-4 Inhibitor Monotherapy
Study Type
Interventional
2. Study Status
Record Verification Date
November 2014
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
August 2012 (Actual)
Study Completion Date
November 2012 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Kissei Pharmaceutical Co., Ltd.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the long-term safety and efficacy of KAD-1229 as combination therapy with biguanide or DPP-4 inhibitor in type 2 diabetes patients who show inadequate glycemic control with diet, and biguanide or DPP-4 inhibitor monotherapy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Type 2 diabetes, HbA1c, Long-term study
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
136 (Actual)
8. Arms, Groups, and Interventions
Arm Title
KAD-1229
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
KAD-1229
Primary Outcome Measure Information:
Title
Incidences of Adverse Events
Time Frame
52 weeks
Secondary Outcome Measure Information:
Title
Change From Baseline in HbA1c at 52 Weeks
Time Frame
at week 0 and week 52
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 diabetes patients who show inadequate glycemic control with diet, and biguanide or DPP-4 inhibitor monotherapy
Age in the 20 years or over inclusive
HbA1c in the range of ≥ 6.5 to < 9%
Exclusion Criteria:
Type 1 diabetes mellitus
Patients with serious diabetic complications and other serious complications
Facility Information:
Facility Name
Japan
City
Kanto region, Chugoku region, Kyushu region
Country
Japan
12. IPD Sharing Statement
Learn more about this trial
Long-term Study of KAD-1229 in Type 2 Diabetes Patients
We'll reach out to this number within 24 hrs